Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T68536
(Former ID: TTDS00308)
|
|||||
Target Name |
Tubulin beta (TUBB)
|
|||||
Synonyms |
Major cysteine proteinase; Cysteine proteinase cruzipain; Cruzaine; Congopain; Beta-tubulin
Click to Show/Hide
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Breast cancer [ICD-11: 2C60-2C6Y] | |||||
2 | Mature B-cell lymphoma [ICD-11: 2A85] | |||||
3 | Parasitic worm infestation [ICD-11: 1F90] | |||||
4 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
Function |
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Click to Show/Hide
|
|||||
BioChemical Class |
Tubulin family
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 5 Approved Drugs | + | ||||
1 | Albendazole | Drug Info | Approved | Worm infection | [2] | |
2 | Mebendazole | Drug Info | Approved | Worm infection | [3] | |
3 | Taxol | Drug Info | Approved | Solid tumour/cancer | [4] | |
4 | Vincristine | Drug Info | Approved | Acute lymphoblastic leukaemia | [5], [6] | |
5 | Vindesine | Drug Info | Approved | Acute lymphoblastic leukaemia | [4], [7] | |
Clinical Trial Drug(s) | [+] 19 Clinical Trial Drugs | + | ||||
1 | Plinabulin | Drug Info | Phase 3 | Non-small-cell lung cancer | [8] | |
2 | Batabulin | Drug Info | Phase 2/3 | Solid tumour/cancer | [9] | |
3 | ABT-751 | Drug Info | Phase 2 | Solid tumour/cancer | [10] | |
4 | BNC-105 | Drug Info | Phase 2 | Mesothelioma | [11] | |
5 | DOLASTATIN-10 | Drug Info | Phase 2 | Solid tumour/cancer | [12] | |
6 | Lexibulin | Drug Info | Phase 2 | Glioblastoma multiforme | [13] | |
7 | T-607 | Drug Info | Phase 2 | Solid tumour/cancer | [14] | |
8 | Verubulin | Drug Info | Phase 2 | Solid tumour/cancer | [15] | |
9 | ZD-6126 | Drug Info | Phase 2 | Solid tumour/cancer | [16] | |
10 | BAL-101553 | Drug Info | Phase 1/2 | Solid tumour/cancer | [17] | |
11 | 1069C | Drug Info | Phase 1 | Solid tumour/cancer | [18] | |
12 | ABI-011 | Drug Info | Phase 1 | Solid tumour/cancer | [19] | |
13 | ALB-109564(a) | Drug Info | Phase 1 | Solid tumour/cancer | [20] | |
14 | CKD-516 | Drug Info | Phase 1 | Solid tumour/cancer | [21] | |
15 | DAVLB-HYDRAZIDE | Drug Info | Phase 1 | Solid tumour/cancer | [22] | |
16 | NSC-639829 | Drug Info | Phase 1 | Solid tumour/cancer | [23] | |
17 | Simotaxel | Drug Info | Phase 1 | Solid tumour/cancer | [24] | |
18 | STA-5312 | Drug Info | Phase 1 | Solid tumour/cancer | [25] | |
19 | Tasidotin hydrochloride | Drug Info | Phase 1 | Solid tumour/cancer | [26] | |
Discontinued Drug(s) | [+] 5 Discontinued Drugs | + | ||||
1 | CEMADOTIN HYDROCHLORIDE | Drug Info | Discontinued in Phase 2 | Solid tumour/cancer | [27] | |
2 | Epothilone D | Drug Info | Discontinued in Phase 2 | Breast cancer | [28] | |
3 | RHIZOXIN | Drug Info | Discontinued in Phase 2 | Breast cancer | [29] | |
4 | S-12363 | Drug Info | Discontinued in Phase 2 | Solid tumour/cancer | [30] | |
5 | Denibulin | Drug Info | Discontinued in Phase 1 | Solid tumour/cancer | [31] | |
Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | ||||
1 | KOS-1803 | Drug Info | Preclinical | Solid tumour/cancer | [32] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Binder | [+] 4 Binder drugs | + | ||||
1 | Albendazole | Drug Info | [33] | |||
2 | Mebendazole | Drug Info | [33] | |||
3 | Vindesine | Drug Info | [1], [36] | |||
4 | Tasidotin hydrochloride | Drug Info | [55] | |||
Modulator | [+] 17 Modulator drugs | + | ||||
1 | Taxol | Drug Info | [34] | |||
2 | Vincristine | Drug Info | [35] | |||
3 | Plinabulin | Drug Info | [37] | |||
4 | ABT-751 | Drug Info | [39] | |||
5 | BNC-105 | Drug Info | [40] | |||
6 | Verubulin | Drug Info | [44] | |||
7 | 1069C | Drug Info | [4], [47] | |||
8 | ABI-011 | Drug Info | [48] | |||
9 | ALB-109564(a) | Drug Info | [49] | |||
10 | DAVLB-HYDRAZIDE | Drug Info | [4], [51] | |||
11 | NSC-639829 | Drug Info | [4], [52] | |||
12 | CEMADOTIN HYDROCHLORIDE | Drug Info | [4], [56] | |||
13 | S-12363 | Drug Info | [59] | |||
14 | APH-0911 | Drug Info | [53] | |||
15 | ARC-200 | Drug Info | [53] | |||
16 | IDN-5390 | Drug Info | [53] | |||
17 | XN-0502 | Drug Info | [53] | |||
Inhibitor | [+] 52 Inhibitor drugs | + | ||||
1 | Batabulin | Drug Info | [38] | |||
2 | DOLASTATIN-10 | Drug Info | [41] | |||
3 | Lexibulin | Drug Info | [42] | |||
4 | T-607 | Drug Info | [43] | |||
5 | ZD-6126 | Drug Info | [45] | |||
6 | BAL-101553 | Drug Info | [46] | |||
7 | CKD-516 | Drug Info | [50] | |||
8 | Simotaxel | Drug Info | [53] | |||
9 | STA-5312 | Drug Info | [4], [54] | |||
10 | Epothilone D | Drug Info | [57] | |||
11 | RHIZOXIN | Drug Info | [58] | |||
12 | Denibulin | Drug Info | [51] | |||
13 | KOS-1803 | Drug Info | [53] | |||
14 | 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene | Drug Info | [60] | |||
15 | 2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene | Drug Info | [60] | |||
16 | 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
17 | 2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde | Drug Info | [62] | |||
18 | 2-amino-3,4',5-trimethoxy-(Z)-stillbene | Drug Info | [60] | |||
19 | 2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one | Drug Info | [63] | |||
20 | 2-m-Tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
21 | 2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol | Drug Info | [64] | |||
22 | 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol | Drug Info | [65] | |||
23 | 2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol | Drug Info | [66] | |||
24 | 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
25 | 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
26 | 3,4',5-trimethoxy-(Z)-stilbene | Drug Info | [60] | |||
27 | 3,4,4',5-tetramethoxy-(Z)-stilbene | Drug Info | [60] | |||
28 | 3-bromo-4,4',5-trimethoxy-(Z)-stilbene | Drug Info | [60] | |||
29 | 5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
30 | 5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
31 | 6-ile-ustiloxin | Drug Info | [41] | |||
32 | 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
33 | 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one | Drug Info | [61] | |||
34 | CENTAUREIDIN | Drug Info | [67] | |||
35 | COLCHINOL | Drug Info | [68] | |||
36 | COMBETASTATIN | Drug Info | [69] | |||
37 | GNF-PF-117 | Drug Info | [70] | |||
38 | Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate | Drug Info | [71] | |||
39 | MR-22388 | Drug Info | [72] | |||
40 | MYOSEVERIN | Drug Info | [73] | |||
41 | N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide | Drug Info | [74] | |||
42 | NSC-106970 | Drug Info | [67] | |||
43 | NSC-664171 | Drug Info | [75] | |||
44 | NSC-679036 | Drug Info | [61] | |||
45 | ON-24160 | Drug Info | [53] | |||
46 | PHENSTATIN | Drug Info | [76] | |||
47 | RTA-301 | Drug Info | [53] | |||
48 | Thiocolchicine | Drug Info | [77] | |||
49 | TL-1892 | Drug Info | [53] | |||
50 | USTILOXIN A | Drug Info | [41] | |||
51 | Ustiloxin D | Drug Info | [41] | |||
52 | Ustiloxin F | Drug Info | [41] |
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 3 KEGG Pathways | + | ||||
1 | Phagosome | |||||
2 | Gap junction | |||||
3 | Pathogenic Escherichia coli infection | |||||
NetPath Pathway | [+] 3 NetPath Pathways | + | ||||
1 | FSH Signaling Pathway | |||||
2 | TCR Signaling Pathway | |||||
3 | EGFR1 Signaling Pathway | |||||
Panther Pathway | [+] 2 Panther Pathways | + | ||||
1 | Cytoskeletal regulation by Rho GTPase | |||||
2 | Huntington disease | |||||
Reactome | [+] 5 Reactome Pathways | + | ||||
1 | Regulation of PLK1 Activity at G2/M Transition | |||||
2 | Loss of Nlp from mitotic centrosomes | |||||
3 | Recruitment of mitotic centrosome proteins and complexes | |||||
4 | Loss of proteins required for interphase microtubule organization?from the centrosome | |||||
5 | Anchoring of the basal body to the plasma membrane | |||||
WikiPathways | [+] 3 WikiPathways | + | ||||
1 | Parkin-Ubiquitin Proteasomal System pathway | |||||
2 | Pathogenic Escherichia coli infection | |||||
3 | Mitotic G2-G2/M phases |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36. | |||||
REF 2 | Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. | |||||
REF 3 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | |||||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785). | |||||
REF 6 | Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry. 2007 Dec 25;46(51):14899-906. | |||||
REF 7 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 9 | ClinicalTrials.gov (NCT00057382) T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients. U.S. National Institutes of Health. | |||||
REF 10 | ClinicalTrials.gov (NCT00436852) ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment. U.S. National Institutes of Health. | |||||
REF 11 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021025) | |||||
REF 12 | ClinicalTrials.gov (NCT00003677) Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | |||||
REF 13 | ClinicalTrials.gov (NCT00664378) Efficacy Study of CYT997 in Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 14 | ClinicalTrials.gov (NCT00054249) T900607 in Treating Patients With Gastroesophageal Junction Cancer. U.S. National Institutes of Health. | |||||
REF 15 | ClinicalTrials.gov (NCT01285414) Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme. U.S. National Institutes of Health. | |||||
REF 16 | ClinicalTrials.gov (NCT00065572) Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV). U.S. National Institutes ofHealth. | |||||
REF 17 | ClinicalTrials.gov (NCT02490800) Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors. | |||||
REF 18 | Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer. 1997;75(4):608-13. | |||||
REF 19 | ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health. | |||||
REF 20 | ClinicalTrials.gov (NCT00724100) A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 21 | ClinicalTrials.gov (NCT01560325) Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers. U.S. National Institutes of Health. | |||||
REF 22 | The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 1991 May 1;51(9):2286-90. | |||||
REF 23 | Phase I Study of Continuous Weekly Dosing of Dimethylamino Benzoylphenylurea (BPU) in Patients with Solid Tumours. Eur J Cancer. 2007 January; 43(1): 78-86. | |||||
REF 24 | ClinicalTrials.gov (NCT00277836) Study Evaluating MST-997 in Advanced Malignant Solid Tumors. U.S. National Institutes of Health. | |||||
REF 25 | ClinicalTrials.gov (NCT00276913) A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | |||||
REF 26 | Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.Clin Cancer Res. 2006 Sep 1;12(17):5207-15. | |||||
REF 27 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006853) | |||||
REF 28 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015773) | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001808) | |||||
REF 30 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000879) | |||||
REF 31 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022182) | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024256) | |||||
REF 33 | Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. | |||||
REF 34 | Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. | |||||
REF 35 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 36 | Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics. 2007 May-Jun;4(3):197-209. | |||||
REF 37 | NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31. | |||||
REF 38 | Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605. | |||||
REF 39 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 40 | The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60. | |||||
REF 41 | Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. | |||||
REF 42 | National Cancer Institute Drug Dictionary (drug id 598799). | |||||
REF 43 | Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476. | |||||
REF 44 | Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54. | |||||
REF 45 | Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67. | |||||
REF 46 | Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. | |||||
REF 47 | Patent WO2005108424 A1. | |||||
REF 48 | Company report (Indena) | |||||
REF 49 | 2010 ASCO Annual Meeting | |||||
REF 50 | CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11. | |||||
REF 51 | An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971. | |||||
REF 52 | Solubilization of NSC-639829. Int J Pharm. 2001 Aug 28;225(1-2):41-7. | |||||
REF 53 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). | |||||
REF 54 | Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 11/2006; 16(19):5164-8. | |||||
REF 55 | Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26. | |||||
REF 56 | Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 1998 Dec 15;37(50):17571-8. | |||||
REF 57 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 58 | Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51. | |||||
REF 59 | Microtubule assembly protects the region 28-38 of the beta- tubulin subunit. Article first published online: 4 FEB 2005. | |||||
REF 60 | 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. | |||||
REF 61 | Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. | |||||
REF 62 | Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem. 1998 Dec 3;41(25):4965-72. | |||||
REF 63 | Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7. | |||||
REF 64 | Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhance... J Med Chem. 1992 Mar 20;35(6):1058-67. | |||||
REF 65 | Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4. | |||||
REF 66 | The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12. | |||||
REF 67 | Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8. | |||||
REF 68 | Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9. | |||||
REF 69 | Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000. | |||||
REF 70 | Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agent... J Med Chem. 1993 Apr 30;36(9):1146-56. | |||||
REF 71 | New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J Med Chem. 2006 Feb 9;49(3):947-54. | |||||
REF 72 | Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem. 2004 Mar 11;47(6):1448-64. | |||||
REF 73 | Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500. | |||||
REF 74 | Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70. | |||||
REF 75 | Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of a... J Med Chem. 1998 Mar 26;41(7):1155-62. | |||||
REF 76 | Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 2002 Jun 6;45(12):2534-42. | |||||
REF 77 | Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)me... J Med Chem. 1993 Mar 5;36(5):544-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.